C4 Therapeutics (CCCC) Capital Expenditures (2019 - 2025)
Historic Capital Expenditures for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $302000.0.
- C4 Therapeutics' Capital Expenditures rose 242307.69% to $302000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $482000.0, marking a year-over-year increase of 4134.9%. This contributed to the annual value of $180000.0 for FY2024, which is 8946.14% down from last year.
- According to the latest figures from Q3 2025, C4 Therapeutics' Capital Expenditures is $302000.0, which was up 242307.69% from -$4000.0 recorded in Q4 2024.
- In the past 5 years, C4 Therapeutics' Capital Expenditures registered a high of $3.1 million during Q2 2022, and its lowest value of -$13000.0 during Q3 2024.
- For the 5-year period, C4 Therapeutics' Capital Expenditures averaged around $597533.3, with its median value being $362000.0 (2023).
- Per our database at Business Quant, C4 Therapeutics' Capital Expenditures tumbled by 10254.78% in 2024 and then soared by 242307.69% in 2025.
- Quarter analysis of 5 years shows C4 Therapeutics' Capital Expenditures stood at $109000.0 in 2021, then skyrocketed by 1266.97% to $1.5 million in 2022, then tumbled by 89.46% to $157000.0 in 2023, then crashed by 102.55% to -$4000.0 in 2024, then soared by 7650.0% to $302000.0 in 2025.
- Its last three reported values are $302000.0 in Q3 2025, -$4000.0 for Q4 2024, and -$13000.0 during Q3 2024.